Robert  Eckert net worth and biography

Robert Eckert Biography and Net Worth

Director of Amgen
Robert A. Eckert is our lead independent director. Mr. Eckert has been an Operating Partner at FFL Partners, LLC (formerly known as Friedman Fleischer & Lowe, LLP), a private equity firm, since 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacture and marketing company, having held this position from 2000 through 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992.

Mr. Eckert has been a director of McDonald’s Corporation, a company that franchises and operates McDonald’s restaurants in the global restaurant industry, since 2003, serving as the Chair of the Public Policy and Strategy Committee and a member of the Executive and Governance Committees. Mr. Eckert also has served as a director of Levi Strauss & Co., a jeans and casual wear manufacturer, since 2010, serving as Chair of the Nominating, Governance and Corporate Citizenship Committee and a member of the Compensation Committee and, since March 2021, as non-executive Chair of the board. In 2020, Mr. Eckert was appointed a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, serving as Chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Eckert was a director of Smart & Final Stores, Inc., a warehouse store, from 2013 until 2014 prior to it becoming a publicly-traded company. He was appointed director of Eyemart Express Holdings LLC, a privately-held eyewear retailer and portfolio company of FFL Partners, LLC, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona. Mr. Eckert received an undergraduate degree from the University of Arizona and a master’s degree in business administration from the Kellogg School of Management at Northwestern University.

What is Robert Eckert's net worth?

The estimated net worth of Robert Eckert is at least $6.48 million as of August 18th, 2022. Mr. Eckert owns 21,184 shares of Amgen stock worth more than $6,482,092 as of June 19th. This net worth approximation does not reflect any other assets that Mr. Eckert may own. Learn More about Robert Eckert's net worth.

How do I contact Robert Eckert?

The corporate mailing address for Mr. Eckert and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Robert Eckert's contact information.

Has Robert Eckert been buying or selling shares of Amgen?

Robert Eckert has not been actively trading shares of Amgen during the last quarter. Most recently, Robert Eckert sold 6,600 shares of the business's stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $249.00, for a transaction totalling $1,643,400.00. Following the completion of the sale, the director now directly owns 21,184 shares of the company's stock, valued at $5,274,816. Learn More on Robert Eckert's trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Robert Bradway (Chairman & CEO), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, Amgen insiders bought shares 1 times. They purchased a total of 1,764,705 shares worth more than $29,999,985.00. During the last year, insiders at the medical research company sold shares 4 times. They sold a total of 23,771 shares worth more than $6,471,488.35. The most recent insider tranaction occured on May, 3rd when SVP Nancy A Grygiel sold 2,117 shares worth more than $662,811.53. Insiders at Amgen own 0.7% of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 5/3/2024.

Robert Eckert Insider Trading History at Amgen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2022Sell6,600$249.00$1,643,400.0021,184View SEC Filing Icon  
See Full Table

Robert Eckert Buying and Selling Activity at Amgen

This chart shows Robert Eckert's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $305.99
Low: $302.02
High: $306.48

50 Day Range

MA: $294.16
Low: $262.75
High: $319.04

2 Week Range

Now: $305.99
Low: $218.44
High: $329.72


2,166,151 shs

Average Volume

2,101,200 shs

Market Capitalization

$164.14 billion

P/E Ratio


Dividend Yield